What Lynch Biologics does

Lynch Biologics, LLC is a Franklin, Tennessee-based biotechnology company that develops, markets, and distributes regenerative biologics for oral and dental surgical applications. Its sole commercial product, GEM 21S, is a synthetic bone graft composed of sterile recombinant human platelet-derived growth factor (rhPDGF-BB) combined with a beta tricalcium phosphate (β-TCP) osteoconductive matrix. It is the first and only FDA-approved recombinant growth factor product for oral regenerative surgery, indicated for intrabony periodontal defects, furcation periodontal defects, and gingival recession associated with periodontal defects. The product works by releasing rhPDGF-BB from the β-TCP scaffold; the protein binds to cell-surface receptors on osteoblasts, periodontal ligament fibroblasts, and cementoblasts, triggering chemotaxis and mitogenesis that drive new bone and soft tissue formation.

The company sells directly to licensed U.S. dentists and physicians through a public e-commerce storefront with publicly disclosed tiered unit pricing ($215-$299 per unit depending on volume) and supplements U.S. sales through a distribution agreement with Lynch Regenerative Medicine (LRM) that goes live in Q2 2026. Canadian distribution is handled exclusively by HANSAmed Limited. Lynch operates as a private subsidiary of Geistlich Pharma North America, Inc., which acquired the company on October 26, 2022, leveraging Geistlich's broader regenerative biomaterials and clinical education channels (e.g., geistlich.us) for cross-promotion. The company's strategic posture, evidenced by the March 2026 creation of LRM Aesthetics and LRM Therapeutics, is to expand the GEM 21S molecule beyond periodontal defects into the broader Pure PDGF portfolio across therapeutic and aesthetic applications.

Name

Lynch Biologics

Legal name

Lynch Biologics, LLC

Website

https://lynchbiologics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Lynch Biologics, LLC is a Franklin, Tennessee-based biotechnology subsidiary of Geistlich Pharma North America that develops and distributes GEM 21S, the only FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) dental bone graft, to licensed dentists and physicians in the U.S. and Canada.

Ownership category

akta.pro rank

Product category

Dental Regenerative Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI)

akta.pro secondary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Dental regeneration
• Bone grafting matrices
• Growth factor therapy
• Periodontal treatment
• Oral surgery biologics

Headquarters

HQ city

Franklin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. GEM 21S Product Sales: Direct product sales of GEM 21S growth-factor enhanced matrix to licensed healthcare providers in the North American dental markets (US & Canada). The company sells directly through its e-commerce storefront at lynchbiologics.com/store/ with tiered pricing based on quantity. Additional distribution is handled through the distribution agreement with Lynch Regenerative Medicine and exclusive Canadian partner HANSAmed Limited.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Lynch Biologics manufactures and sells GEM 21S, a growth-factor enhanced dental regenerative matrix that combines recombinant human platelet-derived growth factor (rhPDGF-BB) with beta-tricalcium phosphate (β-TCP). The product is used in periodontal and oral surgical procedures to support bone and tissue regeneration.

Product overview

Lynch Biologics is a regenerative medicine company and Geistlich North America company offering oral/dental regenerative products. The company operates primarily as a single-product focused business, with GEM 21S as its core offering. GEM 21S is a growth-factor enhanced matrix combining highly purified recombinant human platelet-derived growth factor (rhPDGF-BB) with beta tricalcium phosphate (β-TCP) for bone and soft tissue regeneration in periodontal applications. The company also offers Geistlich Biomaterials as an additional product line through its parent company relationship.

Differentiator

Problem solved

Functional benefit

Brands

• GEM 21S: Growth-factor enhanced matrix product combining recombinant human platelet-derived growth factor (rhPDGF-BB) with beta tricalcium phosphate (β-TCP) for periodontal defect treatment including intrabony defects, furcation defects, and gingival recession associated with periodontal defects.

Products and services

• GEM 21S Growth-Factor Enhanced Matrix A dental regenerative matrix that combines recombinant human platelet-derived growth factor (rhPDGF-BB) with beta-tricalcium phosphate (β-TCP), used by periodontists and oral surgeons for bone and tissue regeneration in periodontal and oral surgical procedures.

Quantifiable outcome

• GEM 21S predictably and dramatically improves ingrowth of regenerative stem cells into grafts within 72 hours
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered major and core.

• Lynch Regenerative Medicine, LLCmajorChannel Partner/ Reseller/ Distributor · 25 March 2026Lynch Regenerative Medicine (LRM) entered into a definitive distribution agreement with Lynch Biologics to commercialize GEM 21S for sale to licensed healthcare providers in the United States. The agreement expands LRM's Pure PDGF portfolio across therapeutic and aesthetic applications and is expected to begin generating sales in Q2 2026. LRM operates under a dual-arm corporate structure with LRM Aesthetics, Inc. and LRM Therapeutics, Inc.
• Geistlich Pharma AG (Parent Company)coreStrategic or Co-development Partner · 26 October 2022On October 26, 2022, Geistlich Pharma North America, Inc. acquired Lynch Biologics, LLC, the developer and sole provider of GEM 21S. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential. The combination expanded regenerative solutions for clinicians and patients, strengthened product development, clinical research, and education on new regenerative technologies.
• HANSAmed LimitedmajorChannel Partner/ Reseller/ DistributorExclusive Canadian distribution partner for Lynch Biologics products including GEM 21S. Promotions may vary in Canada and Puerto Rico. Customers should consult HANSAmed Limited for product availability, pricing, and promotional details specific to the Canadian market.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Dentsply Sirona: One of the largest global dental equipment and supplies companies with a regenerative products portfolio. Provides comparable scope as a broad dental products incumbent with overlap in bone graft and regenerative categories.
• ZimVie: Spun off from Zimmer Biomet with a dental and spine portfolio including RegenerOss bone graft substitutes and other regenerative products. Overlaps with Lynch Biologics in dental bone grafting indications while operating at broader scale.
• Geistlich Pharma AG: Swiss parent company and global leader in dental regeneration with Bio-Oss, Bio-Gide, and BioMatrix brands. While Lynch Biologics is a subsidiary, Geistlich's broader regenerative portfolio overlaps directly with GEM 21S in the same clinical indications.
• Integra LifeSciences: Broad regenerative medicine and surgical specialty company with a dental regenerative portfolio. Overlaps with Lynch Biologics through comparable bone graft substitute offerings while serving a much larger overall footprint.
• Straumann Group: Global leader in dental implants and a growing player in regenerative dentistry through acquisitions. Comparable as a broad dental incumbent expanding into regenerative biologics serving the same clinician base.

Direct peers

• Sunstar Americas: Dental products company with regenerative portfolio including GUIDOR membranes and bone graft substitutes. Directly comparable as a dental regenerative product manufacturer serving periodontists and oral surgeons in similar indications.
• botiss biomaterials: Germany-based dental regenerative medicine company offering bone grafts, membranes, and soft tissue graft products for periodontal and implant procedures. Directly comparable as a dental regenerative biologic specialist competing in similar periodontal and bone augmentation indications as GEM 21S.
• Osteogenics Biomedical: US-based dental regenerative company specializing in bone grafting materials, membranes, and sutures for periodontal and implant procedures. Directly comparable as a focused dental regenerative biologic supplier to periodontists and oral surgeons.

Regional players

• Tecnoss Dental: Italian-based manufacturer of equine-derived and biomimetic bone graft substitutes for dental and orthopedic use. Comparable as a dental regenerative product specialist primarily serving European markets rather than North America.

Emerging players

• LifeNet Health: Non-profit tissue banking and regenerative medicine organization offering allograft bone graft products for dental and orthopedic applications. Comparable as a biologic graft supplier with overlapping dental bone regeneration applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/LynchBio
• LinkedInlinkedin.com/company/lynch-biologics
• Instagraminstagram.com/lynchbiologics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lynch Biologics